Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.48 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CHKA | P35790 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2239373 | 0.95 | HRH3 (0.54) | HRH3CXCR4ALDH1A1KDM4EMEN1 | |
| SCHEMBL2238150 | 0.84 | MCHR1 (0.50) | HRH3ALDH1A1KDM4EOPRM1HDAC1 | |
| SCHEMBL2234834 | 0.82 | ALDH1A1 (0.49) | HRH3CXCR4ALDH1A1KDM4EMEN1 | |
| SCHEMBL2235236 | 0.81 | ALDH1A1 (0.42) | HRH3CXCR4ALDH1A1KDM4EHTT | |
| SCHEMBL2238650 | 0.77 | ALDH1A1 (0.56) | HRH3ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL8844605 | 0.77 | OPRM1 (0.50) | ALDH1A1KDM4EOPRM1MEN1HTT | |
| SCHEMBL18527956 | 0.75 | MEN1 (0.51) | ALDH1A1MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL356816 | 0.75 | MEN1 (0.51) | ALDH1A1MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL8773482 | 0.75 | MEN1 (0.69) | ALDH1A1MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL2238599 | 0.74 | OPRM1 (0.51) | ALDH1A1KDM4EOPRM1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8623859-B2 | Bradykinin B1 antagonists | EVOTEC AG (DE) | 2014-01-07 | — | — | US | disclosed |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | HRH3 11/4885CXCR4 210/4885ALDH1A1 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.